Symposia: Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Combination therapy, Research, Adult, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, B Cell lymphoma, Clinical Research, Chemotherapy, Diseases, Indolent lymphoma, Therapy sequence, Treatment Considerations, Real-world evidence, Aggressive lymphoma, Lymphoid Malignancies, Non-Biological therapies, Study Population, Human, Measurable Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Combination therapy, Research, Adult, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, B Cell lymphoma, Clinical Research, Chemotherapy, Diseases, Indolent lymphoma, Therapy sequence, Treatment Considerations, Real-world evidence, Aggressive lymphoma, Lymphoid Malignancies, Non-Biological therapies, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024: 2:00 PM-3:30 PM
Marriott Grand Ballroom 11-13
(Marriott Marquis San Diego Marina)
Moderators:
Preetesh Jain, MD, MBBS, PhD, DM,
and
Eva Gine, MD, Hospital Clinic of Barcelona. IDIBAPS. University of Barcelona
Disclosures:
Gine: Janssen: Honoraria, Research Funding; Lilly: Honoraria, Research Funding; Roche: Honoraria; Gilead/Kite: Honoraria; Astra-Zeneca: Honoraria.
The oral session 1 focus on Mantle cell lymphoma (as 6 of the top abstracts were of MCL). It contains 4 clinical trials (first 4 abstracts) and 2 studies reporting the outcome of patients after CART progression or relapse.
2:00 PM
2:15 PM
2:30 PM
2:45 PM
3:00 PM
3:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH